A phase II study of weekly docetaxel (T), estramustine (E), and celecoxib (C) in patients with hormone refractory prostate cancer (HRPC).

被引：0
|
作者：
Mellado, B
Font, A
Carles, J
Catalán, G
Larriba, JLG
Gallardo, E
Fernández, LA
Nogué, M
Lianes, P
Del Alba, AG
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Univ Barcelona, Hosp Germans Trias & Pujol, Barcelona, Spain
[3] Hosp del Mar, Barcelona, Spain
[4] Hosp Son Liatzer, Islas Baleares, Spain
[5] Hosp Clin San Carlos, Madrid, Spain
[6] Corp Sanitaria Parc Tauli, Barcelona, Spain
[7] Hosp Terrassa, Barcelona, Spain
[8] Hosp Gen Vic, Barcelona, Spain
[9] Hosp Mataro, Barcelona, Spain
[10] Hosp Son Dureta, Islas Baleares, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：434S / 434S
页数：1
相关论文
共 50 条
  • [21] The addition of imatinib mesylate to estramustine/docetaxel (E/D) for the treatment of hormone refractory prostate cancer (HRPC) patients: Results of a phase I trial.
    Randall, M
    Rini, B
    Ryan, C
    Rosenberg, J
    Garcia, J
    Bubley, G
    Small, EJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 411S - 411S
  • [22] Phase II trial of docetaxel (D) and high-dose celecoxib (C) in patients (Pts) with hormone resistant prostate cancer (HRPC).
    Kasimis, B
    Cogswell, J
    Hwang, S
    Chang, V
    Llorente, M
    Boholli, I
    Srinivas, S
    Morales, E
    Davis, C
    Blumenfrucht, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 410S - 410S
  • [23] Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition:: Preliminary results of a multicenter phase II study (AUO AP33/02).
    Miller, E
    Wülfing, C
    Lehmann, J
    Johannsen, M
    Heidenreich, A
    Hegele, A
    Backhaus, B
    Steiner, U
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 406S - 406S
  • [24] Docetaxel (D) plus estramustine (E) versus D alone in patients (pts) with hormone-refractory prostate cancer (HRPC): Updated analysis of a phase II randomized trial
    Mousseau, Mireille
    Joly, Florence
    Priou, Franck
    Zannetti, Alain
    Ravaud, Alain
    Kerbrat, Pierre
    Paule, Bernard
    Touze, Florence
    Ecstein-Fraisse, Evelyne
    Eymard, Jean-Christophe
    ANNALS OF ONCOLOGY, 2004, 15 : 114 - 114
  • [25] Phase II study of docetaxel and thalidomide in Japanese patients with prostate cancer refractory to hormone and DEC (docetaxel, estramustine phosphate, and carboplatin) therapy
    Honda, Satoshi
    Inoue, Keita
    Kobara, Chiaki
    Arichi, Naoko
    Mitsui, Yozo
    Hiraoka, Takeo
    Wake, Koji
    Sumura, Masahiro
    Yasumoto, Hiroaki
    Shiina, Hiroaki
    Igawa, Mikio
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 : A294 - A295
  • [26] Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC).
    Nelius, T.
    Klatte, T.
    Reiher, F.
    Filleur, S.
    Yap, R.
    Allhoff, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 254S - 254S
  • [27] Randomised study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [28] A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC).
    Caffo, O.
    Sava, T.
    Comploj, E.
    Fariello, A.
    Zustovich, F.
    Valduga, F.
    Frisinghelli, M.
    Segati, R.
    Sacco, C.
    Perin, A.
    Pappagallo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 247S - 247S
  • [29] A phase II trial of 13-cis retinoic acid, interferon, docetaxel, and estramustine (RITE) for the treatment of hormone refractory prostate cancer (HRPC)
    Mehta, A.
    Stein, M. N.
    Goodin, S.
    Doyle-Lindrud, S.
    Todd, M.
    Rubin, E.
    White, E.
    Jeyamohan, C.
    Metzger, D.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] A phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC)
    George, DJ
    Gockerman, JP
    Petros, W
    Haley, S
    Franklin, AD
    Creel, PA
    Turner, AG
    Sleep, D
    Hurwitz, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 419S - 419S
12345